Subscribe To Print Edition About The Tribune Code Of Ethics Download App Advertise with us Classifieds

Advertisement

Monoclonal antibody mix cuts Covid hospital deaths

New Delhi: The University of Oxford led Recovery Trials working to search Covid-19 treatments said on Wednesday they had for the first time found an antiviral treatment saving lives of hospitalised patients. The trial demonstrated that the investigational antibody combination...

Tribune News Service

Updated At : 11:38 AM Jun 17, 2021 IST

featured-img

Advertisement

New Delhi: The University of Oxford led Recovery Trials working to search Covid-19 treatments said on Wednesday they had for the first time found an antiviral treatment saving lives of hospitalised patients.

The trial demonstrated that the investigational antibody combination developed by US biotechnology giant Regeneron reduced the risk of death by a fifth when given to hospitalised patients. The treatment uses a combination of two monoclonal antibodies (casirivimab and imdevimab) that bind specifically to two different sites on the coronavirus spike protein, neutralising the ability of the virus to infect cells. TNS

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Copyright © The Tribune Trust, 2024

Designed and developed by :